What Accsys Technology does

AccSys Technology, Inc. is an integrated design and manufacturing firm specializing in ion linear accelerator (linac) systems for medical, industrial, and research applications. Founded in 1985 and headquartered at 1177 Quarry Lane, Pleasanton, California, the company builds compact proton and ion accelerators based on proprietary radiofrequency quadrupole (RFQ) and drift-tube linac (DTL) technology, protected by two foundational US patents — US 5,315,120 ("Univane" RFQ design) and US 5,179,350 (DTL mounting scheme). Its product portfolio spans four lines: PULSAR® (compact proton linacs for PET isotope production in hospitals), LANSAR® (linear-accelerator-based neutron generators for non-destructive inspection), LiNSTAR™ (synchrotron injector linacs at 2–7 MeV for proton therapy and research), and Custom Linacs (high-current pulsed proton systems from 2 MeV to above 100 MeV), supported by shared subsystems including RF power systems (150–600 MHz, 25–360 kW peak power).

The company sells directly to a global base of hospitals, research institutions, and industrial customers through a project-oriented sales approach that bundles system design, facility planning, flexible financing, installation, operator training, warranty, and service contracts. Hardware is delivered as complete systems or as modular subsystems that support field upgrades — e.g., PULSAR 7 to PULSAR 11 — creating a recurring aftermarket revenue layer on top of one-time capital sales. Reference customers include Loma Linda University Proton Cancer Treatment Center (continuous operation since 1990), Brookhaven National Laboratory (joint R&D partner on PULSAR targets and chemistry), and Hitachi General Hospital (first PULSAR 7 installation in 2004).

AccSys Technology was demerged from Performance Controls, Inc. — a Hitachi, Ltd. division — and became an independent corporation on April 1, 2020, while remaining wholly owned by Hitachi, Ltd. (TSE: 6501). It operates as a private subsidiary of a Japanese conglomerate with no disclosed venture capital or private equity investment, ~51–100 employees, and no publicly disclosed revenue. Its competitive position is anchored by decades of installed-base credibility, patented core technology, and a cost architecture that competes with traditional cyclotrons on footprint, lifecycle cost, and decommissioning burden.

Name

Accsys Technology

Legal name

AccSys Technology, Inc.

Website

https://accsys.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

AccSys Technology, Inc. designs and manufactures ion linear accelerator systems (RFQ and DTL) for PET isotope production, neutron generation, and synchrotron injection, serving hospitals, research labs, and industrial customers worldwide from Pleasanton, California. Wholly owned by Hitachi, Ltd.

Ownership category

akta.pro rank

Product category

Particle Accelerator Systems / Ion Linear Accelerators

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

Keywords

• Ion linear accelerators
• Proton linac systems
• PET isotope production
• Neutron generators
• Synchrotron injectors

Headquarters

HQ city

Pleasanton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Others

Revenue model

1. Linear Accelerator Hardware Sales: AccSys generates revenue through the sale of ion linear accelerator systems, including standard product lines (PULSAR, LANSAR, LiNSTAR) and custom-designed systems. Hardware includes RFQ linacs, DTL linacs, and RF power systems as complete systems or subsystems.
2. Professional Services and Support: Revenue from comprehensive customer support including design services, facility planning, equipment installation, operator training, warranty programs, and service contract options.
3. System Upgrades and Reconfiguration: Modular subsystem design allows customers to upgrade features, functions and performance from PULSAR 7 to PULSAR 11 and higher energy systems, providing ongoing revenue opportunities.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

AccSys Technology designs, manufactures, installs, and services ion linear accelerator (linac) systems based on its patented RFQ linac and drift-tube linac (DTL) technology. It sells compact proton linac systems for PET isotope production (PULSAR®), linac-based neutron generators for industrial and research use (LANSAR®), ion linacs for synchrotron injection in proton therapy and physics research (LiNSTAR™), and custom-engineered high-current pulsed proton linacs (PL-Series / Custom Linacs), with supporting RF power systems.

Product overview

AccSys Technology is an integrated design and manufacturing company specializing in ion linear accelerator (linac) systems using radiofrequency quadrupole (RFQ) linac and drift-tube linac (DTL) technology. The company's product portfolio consists of four core branded systems: PULSAR® (PET isotope production linacs for medical imaging), LANSAR® (neutron generators for industrial/research applications), LiNSTAR™ (synchrotron injector linacs for proton beam therapy and physics research), and Custom Linacs (tailored systems for specialized ion beam applications). These products share common underlying technology components including proprietary RFQ linacs, DTL, and RF power systems. AccSys serves customers in medicine, industry, and research worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• PULSAR®: Compact proton linac systems for cost-effective production of radiotracers for Positron Emission Tomography (PET) imaging applications.
• LANSAR®
• LiNSTAR™

Products and services

• PULSAR® PET Isotope Production Systems Compact proton linac-based systems for the cost-effective production of positron emitting radiotracers (fluorine-18 and carbon-11) used in Positron Emission Tomography (PET) imaging for oncology, cardiology, neurology, and molecular imaging. Available as standalone installations or in mobile configurations inside standard 48 ft trailers. Designed for hospitals and medical imaging centers that need reliable PET isotope supply without the footprint, cost, or decommissioning burden of a traditional cyclotron.
• LANSAR® Neutron Generator Systems Versatile line of linear-accelerator-based compact neutron generators for non-destructive inspection applications. Uses AccSys' patented linac technology with customer-supplied targets, with no radioactive materials, rugged transportable construction, computerized control and monitoring, and variable intensity and pulse structure. Built for reliable long-term operation in research and industrial environments.
• LiNSTAR™ Synchrotron Injector Systems Family of ion linac systems engineered to inject ion beams into synchrotrons used in proton beam cancer therapy and physics research. Standard systems deliver output beam energies from 2 to 7 MeV, with higher injection energies available as custom configurations. Targeted at hospitals with proton therapy programs and physics research institutions operating synchrotron facilities.
• Custom Linacs (PL-Series High-Current Pulsed Proton Linacs) Custom-engineered high-current pulsed proton linacs delivering a wide range of peak and average currents at energies from 2 MeV to above 100 MeV. Pulse width, energy, and current can be varied from pulse to pulse so a single accelerator can serve multiple targets or applications. Built from modular subsystems (RFQ linacs, DTL, RF power systems, HEBT, buncher cavities) tailored to customer specifications for synchrotron injection, isotope production research, and specialized physics and industrial uses.

Quantifiable outcome

• Systems can be installed in less than 1,000 ft² for complete PET radiotracer production facility
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Hitachi, Ltd.minorStrategic or Co-development Partner · 1 April 2020Former parent company that demerged AccSys Technology as an independent company effective April 1, 2020. AccSys was previously part of Performance Controls, Inc., a division of Hitachi, Ltd. The demerger was part of Hitachi's sale of diagnostic imaging businesses announced December 18, 2019. AccSys continues to operate as wholly owned by Hitachi Ltd. with same 'ship to' and 'bill to' addresses.
• Brookhaven National LaboratorycoreStrategic or Co-development PartnerJoint research and development agreement for PULSAR isotope production targets and chemistry systems. The PET chemistry group at Brookhaven National Laboratory collaborated with AccSys on developing precision, high performance targets and radiotracer synthesis units that are efficient, reliable and easy to use.
• Medical CoachesminorOEM/ Whitelabel/ Licensing PartnerPartnership for Mobile PET Isotope Production Lab. Medical Coaches provides the trailer that contains the linac room and laboratory area with clean room for manufacturing, dispensing FDG and chemical handling. The Mobile PULSAR 7 is provided in a standard 48 ft trailer configuration.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Neutron Therapeutics: Developer of accelerator-based neutron sources for boron neutron capture therapy (BNCT). Uses linac technology similar in principle to AccSys's LANSAR neutron generator platform, targeting emerging clinical and research BNCT applications.
• Mevion Medical Systems: US-based developer of compact single-room proton therapy systems that compete with traditional synchrotron-based proton centers. Adjacent to AccSys LiNSTAR because proton therapy center growth drives demand for both injector linacs and competing delivery architectures.
• ProNova Solutions: Compact proton therapy system developer targeting single-room installations. Indirectly comparable to AccSys because both target smaller, lower-cost proton therapy deployments, though at different layers of the delivery stack.

Broad incumbents

• Varian Medical Systems (a Siemens Healthineers company): Major radiation oncology vendor now owned by Siemens Healthineers, active in proton therapy systems and imaging for treatment planning. Competes with AccSys's LiNSTAR injector business indirectly through integrated proton therapy platform offerings.
• Siemens Healthineers: Global medical technology company with PET imaging hardware, radiopharmacy solutions, and (post-Varian acquisition) proton therapy and radiation oncology. Overlaps with AccSys PULSAR in PET isotope production and with LiNSTAR through Varian's particle therapy footprint.
• GE HealthCare: Large medical imaging OEM with an established PET radiopharmacy/cyclotron business (historically via PETtrace) and broader molecular imaging portfolio. Competes with AccSys PULSAR through entrenched cyclotron installations and integrated radiopharmacy service offerings.

Direct peers

• IBA (Ion Beam Applications): Belgian leader in PET radioisotope cyclotrons and proton therapy systems. Directly competes with AccSys PULSAR in medical PET isotope production and with LiNSTAR in proton therapy injector/accelerator supply.
• Best Cyclotron Systems: US-based designer and manufacturer of medical cyclotrons, primarily for PET isotope production and proton therapy. Competes head-to-head with AccSys PULSAR for hospital and research site PET installations.
• Sumitomo Heavy Industries: Japan-based manufacturer of medical cyclotrons for PET isotopes and proton therapy systems. Closely comparable to AccSys across both the PULSAR product line and the LiNSTAR synchrotron injector business.

Others

• Hitachi, Ltd. (parent group and adjacent particle therapy business): AccSys's parent company, which operates its own proton beam therapy systems business. Relevant as the corporate parent providing capital, channels, and Hitachi General Hospital as a reference customer, while also fielding competing particle therapy technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AccSysTech

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accsys Technology